Ohno Makoto, Narita Yoshitaka, Miyakita Yasuji, Okita Yoshiko, Kayama Takamasa, Shibui Soichiro
Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Asia Pac J Clin Oncol. 2012 Dec;8(4):e49-52. doi: 10.1111/j.1743-7563.2012.01561.x. Epub 2012 Jun 15.
Secondary cancer is a serious late complication in childhood leukemia survivors. Here, we report a case of secondary skull sarcoma developing after treatment for childhood acute myeloid leukemia, including bone marrow transplantation (BMT). This patient had breast cancer 1 year before treatment for the skull sarcoma. The patient underwent macroscopic total removal of the skull tumor with bone margin with postoperative radiation therapy and did not develop tumor recurrence for 25 months. Our patient's experience suggests that survivors of childhood leukemia are at risk of developing skull sarcoma and that multi-agent chemotherapy, including anthracycline, TBI used as conditioning for BMT, and development of GVHD, are possible risk factors. Considering the possibility of multiple secondary malignancies in such patients, careful long-term follow up is mandatory.
继发性癌症是儿童白血病幸存者严重的晚期并发症。在此,我们报告一例儿童急性髓系白血病治疗后发生的继发性颅骨肉瘤病例,包括骨髓移植(BMT)。该患者在颅骨肉瘤治疗前1年曾患乳腺癌。患者接受了颅骨肿瘤连同骨边缘的宏观全切术,并术后接受放射治疗,25个月未出现肿瘤复发。我们患者的经历表明,儿童白血病幸存者有发生颅骨肉瘤的风险,多药化疗,包括蒽环类药物、用作BMT预处理的全身照射(TBI)以及移植物抗宿主病(GVHD)的发生,可能是风险因素。考虑到此类患者发生多种继发性恶性肿瘤的可能性,必须进行仔细的长期随访。